Tag: Hua Medicine
Founder of Hua Medicine Dr. Chen Li was awarded the ‘C.C....
The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and...
Hua Medicine Announces 2023 Interim Results
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at the end...
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin...
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class...
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial
Figure 1
<img src="https://www.businessnewsasia.com/wp-content/uploads/2020/06/HuaMed2-300x36.jpg" alt="HbA1c Reduction *p HbA1c Reduction *p
Hua Medicine (the "Company",...
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin...
Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112.
HMM0112...
Hua Medicine Announces 2019 Annual Results
Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 WeeksDorzagliatin-Driven Portfolio Expands
Hua Medicine (the "Company", Stock Code...
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer,...
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua...
